Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Soft Tissue Sarcoma (STS) Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab, Doxorubicin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
30
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced May 21, 2026, 8:12 PM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
Interventions
YH001, Envafolimab, Doxorubicin
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Santa Monica, California • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced May 21, 2026, 8:12 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma
Interventions
Avastin, Doxorubicin
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced May 21, 2026, 8:12 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
Interventions
Lymphodepletion, TCR-T cells (MDG1015)
Drug · Biological
Lead sponsor
Medigene AG
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Olaratumab, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
Gemcitabine, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced May 21, 2026, 8:12 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
Interventions
GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab, eribulin, trastuzumab deruxtecan (T-DXd), pembrolizumab
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced May 21, 2026, 8:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma
Interventions
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Evanston, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced May 21, 2026, 8:12 PM EDT
Not yet recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Soft Tissue Sarcoma (STS)
Interventions
5-ALA
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 8:12 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma
Interventions
[Ga-68]-PNT6555, [Lu-177]-PNT6555
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced May 21, 2026, 8:12 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Interventions
ADI PEG20, Ifosfamide, Radiotherapy, Mesna
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 8:12 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
Interventions
Trabectedin, Ipilimumab, Nivolumab
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced May 21, 2026, 8:12 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions
Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
soblidotin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Sarcoma,Soft Tissue, Pulmonary Metastasis
Interventions
Liposomal Annamycin (L-Annamycin)
Drug
Lead sponsor
Moleculin Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Santa Monica, California • St Louis, Missouri • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced May 21, 2026, 8:12 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0405
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced May 21, 2026, 8:12 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Atezolizumab, Doxorubicin Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma
Interventions
TRC105 and Pazopanib
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 120 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced May 21, 2026, 8:12 PM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0111
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced May 21, 2026, 8:12 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced May 21, 2026, 8:12 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced May 21, 2026, 8:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Interventions
1.0% IP-001 for Injection
Drug
Lead sponsor
Immunophotonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced May 21, 2026, 8:12 PM EDT